| Sharon Lynn Weintraub, MD | |
|
100 Grand Street, The Hospital Of Central Connecticut, New Britain, CT 06052 | |
| (860) 224-5513 | |
| (860) 224-5713 |
| Full Name | Sharon Lynn Weintraub |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 29 Years |
| Location | 100 Grand Street, New Britain, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639180151 | NPI | - | NPPES |
| 1186988 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | 051417 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Hospital Of Central Connecticut At New Britain General And Bradley | 6507776564 | 321 |
News Archive
Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.
Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.
On New Year's Eve of 2012, the US Food and Drug Administration (FDA) announced its approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, Ltd., Raleigh, North Carolina) — marking the second time a botanical, and the first time an orally administered botanical, has received drug approval from the Administration.
› Verified 2 days ago
| Entity Name | The Hospital Of Central Connecticut At New Britain General And Bradley |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063461481 PECOS PAC ID: 6507776564 Enrollment ID: O20040115000497 |
News Archive
Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.
Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.
On New Year's Eve of 2012, the US Food and Drug Administration (FDA) announced its approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, Ltd., Raleigh, North Carolina) — marking the second time a botanical, and the first time an orally administered botanical, has received drug approval from the Administration.
› Verified 2 days ago
| Entity Name | Midstate Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154425288 PECOS PAC ID: 7416840699 Enrollment ID: O20040203000244 |
News Archive
Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.
Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.
On New Year's Eve of 2012, the US Food and Drug Administration (FDA) announced its approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, Ltd., Raleigh, North Carolina) — marking the second time a botanical, and the first time an orally administered botanical, has received drug approval from the Administration.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sharon Lynn Weintraub, MD 100 Grand Street, The Hospital Of Central Connecticut, Dept Of Surgery, New Britain, CT 06052 Ph: (860) 224-5513 | Sharon Lynn Weintraub, MD 100 Grand Street, The Hospital Of Central Connecticut, New Britain, CT 06052 Ph: (860) 224-5513 |
News Archive
Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.
Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn's disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai's Humira will increase to 36 percent.
On New Year's Eve of 2012, the US Food and Drug Administration (FDA) announced its approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, Ltd., Raleigh, North Carolina) — marking the second time a botanical, and the first time an orally administered botanical, has received drug approval from the Administration.
› Verified 2 days ago
Dr. Noubar Movses Kevorkian, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-224-5513 Fax: 860-224-5916 | |
Parth S Shah, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 40 Hart St, Bldg C, New Britain, CT 06052 Phone: 860-229-8889 Fax: 860-229-8893 | |
Mr. Terrence K Donahue, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 40 Hart Street, Bldg D, New Britain, CT 06052 Phone: 860-826-5288 Fax: 860-225-9519 | |
Elizabeth Roderick, MD Surgery Medicare: Medicare Enrolled Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-972-9093 | |
Dr. Robert Napoletano, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Lake St, Grove Hill Medical Center, New Britain, CT 06052 Phone: 860-826-4457 Fax: 860-229-6963 | |
Justin Van Backer, Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St Dept Of, New Britain, CT 06052 Phone: 860-696-4923 | |
Christine Marie Bartus, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 40 Hart St, Building C, New Britain, CT 06052 Phone: 860-229-8889 Fax: 860-229-8893 |